Pancrelipase delayed release - Allergan

Drug Profile

Pancrelipase delayed release - Allergan

Alternative Names: APT-1008; Enzepi; EUR-1008; EUR-1008M; Zenpep; Zentase

Latest Information Update: 13 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eurand
  • Developer Allergan
  • Class Pancreatic enzymes
  • Mechanism of Action Pancrelipase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pancreatic disorders

Most Recent Events

  • 13 Mar 2018 Discontinued - Phase-III for Pancreatic disorders in Ukraine (PO) (NCT00788593)
  • 29 Apr 2016 The Committee for Medicinal Products for Human Use recommends approval of Pancrelipase for Pancreatic disorders (exocrine pancreatic insufficiency in patients with cystic fibrosis) in EU
  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top